||Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2012, vol. 18, book 3;
Subject Collection: Medicine
Published online: 21 December 2012
J of IMAB. 2012; 18(3):345-348
CHANGES IN THE IMMUNOLOGIC MARKERS OF ELASTIN DEGRADATION IN SUBJECTS WITH METABOLIC SYNDROME
Edward Mekenyan, Nadya Stancheva, Snejana Tisheva
First Cardiological Clinic UMPHAT "G. Stranski" - Pleven, Bulgaria.
Background: It is known that metabolic syndrome characterized by diabetes, hypertension, dyslipidemia, and central obesity is associated with the syndrome of early vessels aging, characterized by a change in elasticity of the vessel wall. The early manifestation of the metabolic syndrome in younger people in the modern society, leads to earlier manifestation of the complications of early vessels aging, and the combination of several risk factors is crucial and leads to acceleration of the vessels aging. Elastin is one of the main building blocks of the of the vessel wall. Its main characteristic is its elasticity, allowing the vessel to restore its shape after stretching or shrinking. Loss of elasticity is a key component in the pathogenesis of cardiovascular complications
Materials and methods: A study is conducted on 62 subjects with metabolic syndrome without vascular complications and 42 controls. The main objective of the study was to compare the imunological markers of elastin degradation in both groups and to assess their relationship with the risk factors characterizing the metabolic syndrome.
Results: When comparing the mean value of AEAb IgG in the control group and subject group with metabolic syndrome (respectively 0,45 / - 0.11 and 0.54 / - 0.29) statistically significant higher mean value of AEAb IgG in the group with metabolic syndrome, t = -1,85, p = 0.03 is observed. When comparing the mean value of ATEAb IgG in the control group and subject group with metabolic syndrome (respectively 0,45 / - 0.13 and 0.55 / - .43) statistically significant higher mean value of ATAb IgG in the group with metabolic syndrome, F = 6,83, p = 0.01 is observed. There isn’t a statistically significant difference in AEAb IGM and ATropoEAb IgM in both groups. In the whole sample AEAb IgG showed positive correlation with total cholesterol with a correlation Spearman coefficient r = 0,25, and p = 0,02, with triglyceride levels with Pearson correlation coefficient of r = 0,35, p = 0,001 and with LDL levels with Spearman correlation coefficient r = 0,29, and p = 0,006. In the whole sample ATropoEAb IgG showed positive correlation with LDL levels with Spearman correlation coefficient r = 0,29, p = 0,006 and with levels of total cholesterol with a Pearson correlation coefficient r = 0,33, and p = 0,001. The Correlations are described by regression analysis and the relationship is linear.
Conclusion: It is proved that the AEAb IgG and AtropoEAb IgG are significantly elevated in the subjects with metabolic syndrome without manifested cardiovascular complications compared with the control group, whereas no difference in AEAb IgM and ATropoEAb IgM has been observed in the both groups.
Key words: Metabolic syndrome, AEAb IgG, ATEAb IgG, risk factor.
- Download FULL TEXT /PDF 1058 KB/
Please cite this article as: Mekenyan E, Stancheva N, Tisheva S. CHANGES IN THE IMMUNOLOGIC MARKERS OF ELASTIN DEGRADATION IN SUBJECTS WITH METABOLIC SYNDROME. J of IMAB. 2012; 18(3):345-348. doi: 10.5272/jimab.2012183.345.
1. Frohlich ED, Susic D. Blood pressure, large arteries and atherosclerosis. In: Safar ME, Frohlich ED (eds): Atherosclerosis, Large Arteries and Cardiovascular Risk. Adv Cardiol. Basel, Karger. 2007; 44:117-124. [PubMed] [CrossRef]
2. Vague J. Sexual differentiation, a factor affecting the forms of obesity. Presse Med. 1947; 30:339-40
3. International Diabetes Federation. The IDF worldwide definition of the metabolic syndrome. April 14, 2005 www.idf.org/webdata/docs/Metac_syndrome_def.pdf
4. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001 Apr;24(4):683-689. [PubMed] [CrossRef]
5. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care. 2002 Oct;25(10):1790-4. [PubMed] [CrossRef]
6. Akhtar S, Meek KM, James V. Immunolocalization of elastin, collagen type I and type III, fibronectin, amd vitronectin in extra-cellular matrix components of normal and myxomatous mitral heart valve chordae tendineae. Cardiovasc Pathol. 1999 Jul-Aug;8(4): 203-1. [PubMed] [CrossRef]
7. Mayne R, Brewton RG. New members of the collagen superfamily. Curr Opin Cell Biol. 1993; Oct; 5(5): 883-90. [PubMed]
8. Mecham RP, Hinek A, Grifin GL, Senior RM, Liotta LA. The Elastin receptor shows structural and functional similarities to the 67-kDa tumor cell laminin receptor. J Biol Chem. 1989 Oct 5;264(28):16652-7. [PubMed]
9. Belz GG. Elastic properties and Windkessel function of the human aorta. Cardiovasc Drugs Ther. 1995 Feb;9(1):73–83. [PubMed]
10. Nicoloff G, Weiss AS, Iotova V, Tzaneva V, Petrova C, Domuschieva N, et al. Abnormal levels of serum antielastin antibodies in children with diabetes mellitus type 1. J Investig Med. 2006 Dec;54(8):461-7. [Pubmed] [CrossRef]
11. S. Tisheva. Changes in elastin degradation immunological indices in patients with moderate arterial hypertension maintained on systematic antihypertension treatment. Biotechnol&Biotechnol Eq. 2005 Sep;19(3):149-159.
12. Bizbiz L, Alpérovitch A, Robert L. Aging of the vascular wall: serum concentration of elastin peptides and elastase inhibitors in relation to cardiovascular risk factors. The EVA study. Atherosclerosis. 1997 May;131(1):73-8. [PubMed]
13. Baydanoff S, Nicoloff G, Alexiev C. Age-related changes in the level of circulating elastin-derived peptides in serum from normal and atherosclerotic subjects Atherosclerosis. 1987 Jul;66(1–2):163–168. [PubMed]
14. Daskalova M, Taskov H, Dimitrova E, Baydanoff S. Humoral and Cellular Immune Response to Elastin in Patients with Systemic Sclerosis. Autoimmunity. 1997; 25(4):233-241. [PubMed]
15. Nicoloff G, Christova P. Elastin degradation products among obese children with family history of arterial hypertension. Diabetologia Croatica. 2003; 32(1):25-27.
16. Gminski J, Drozdz M, Ulfig-Maslanka R, Najda J. Evaluation of elastin metabolism in children from families with high risk of atherosclerosis. Atherosclerosis. 1991 Dec;91(3):185-189. [PubMed]
17. Lindholt JS, Heickendorff L, Antonen S, Fasting H, Hennenberg EW. Natural history of abdominal aortic aneurysm with and without coexisting chronic obstructive pulmonary disease. J Vasc Surg. 1998; 28:226-233. [PubMed]
18. Nicoloff G, Baydanoff S, Stanimirova N, Petrova C, Christova P. An association of anti-elastin IgA antibodies with development of retinopathy in diabetic children. Gen Pharmacology. 2000 Aug;35(2):83-87. [PubMed] [CrossRef]
19. Atanasova M, Konova K, Georgieva M, Dimitrova A, Coquand-Gandit M, Faury G, et al. Age-Related Changes of Anti-Elastin Antibodies in Senescence-Accelerated Mice. Gerontology. 2010; 56(3):310-318. [PubMed] [CrossRef]
20. Fulop T Jr, Jacob MP, Robert L. Determination of anti-elastin peptide antibodies in normal and arteriosclerotic human sera by ELISA. J Clin Lab Immunol. 1989 Oct;30(2):69-74. [PubMed]
21. Bako G, Jacob MP, Fulop T Jr, Foris G, Leovey A, Robert L. Immunology of elastin: study of anti-elastin peptide antibodies by DOT immunobinding assay. Immunol Lett. 1987 Jul;15(3):187-192. [PubMed].
Accepted for publication: 26 September 2012
Issue published online: 21 December 2012
back to Online Journal